Management options, survivorship, and emerging treatment strategies for follicular and Hodgkin lymphomas

Leukemia and Lymphoma

Volumn 51, Issue SUPPL. 1, 2010, Pages 41-49

  Czuczman, Myron ^a   Straus, David ^b   Gribben, John ^c   Bredenfeld, Henning ^d   Friedberg, Jonathan ^e   Bollard, Catherine ^f  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Follicular lymphoma; Hodgkin lymphoma; survivorship

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CD20 ANTIGEN; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; FLUDARABINE; IBRITUMOMAB TIUXETAN; PREDNISONE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

AUTONOMIC DYSFUNCTION; AZOOSPERMIA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CELL TRANSPLANTATION; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; DRUG EFFICACY; ETHNICITY; FEMALE INFERTILITY; FOLLICULAR LYMPHOMA; HEART ARRHYTHMIA; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; MONOTHERAPY; OSTEOPOROSIS; PERICARDIAL DISEASE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RADIOIMMUNOTHERAPY; REVIEW; RHEUMATIC HEART DISEASE; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR BIOPSY;

ANTINEOPLASTIC AGENTS; DISEASE MANAGEMENT; HODGKIN DISEASE; HUMANS; LYMPHOMA, FOLLICULAR; REMISSION INDUCTION; SURVIVAL RATE;

EID: 77956441369     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.500083     Document Type: Review

References (60)

1. Stedmans concise medical dictionary (28th revised edition). Baltimore, MD: Lippincott Williams and Wilkins, 2005.
2. Friedberg JW. Treatment of follicular NHL: the old and the new. Semin Hematol 2008;45(3 Suppl. 2):S2-S6.
3. American Cancer Society. Outlook brighter for patients with follicular lymphoma. 2009B; Available from: http://www.cancer. org/docroot/NWS/content/NWS- 11x-Outlook-Brighter-for- Patients-With-Follicular-Lymphoma.asp [Accessed 17 November 2009].
4. Salles GA. Clinical features, prognosis and treatment of follicular lymphoma. Hematology Am Soc Hematol Educ Progr 2007;216-225.
5. American Cancer Society. What are the key statistics about Hodgkin disease? 2009A; Available from: http://www.cancer. org/docroot/CRI/content/CRI- 2-4-1x-What-Are-the-Key- Statistics-About-Hodgkin-Disease.asp [Accessed 17 November 2009].
6. National Cancer Institute. SEER incidence- crude rates for white/black/other, 1973-2006. 2009; Available from: http://canques.seer.cancer. gov/cgi-bin/cq-submit?dirseer2006&db 4&rptLINE&sel10790& xAge%20at%20diagnosis6, 7,8,9,10,11,12,13,14,15,16,17,18,19,20&yRace0,1, 2Sex0,1, 2&dec1&templatenull [Accessed 17 November 2009].
7. Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004;104:3483-3489.
8. Rueda Dominguez A, Marquez A, Guma J, et al. Treatment of stage I and II Hodgkins lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. Ann Oncol 2004;15:1798-1804.
9. Klimm B, Schnell R, Diehl V, Engert A. Current treatment and immunotherapy of Hodgkins lymphoma. Haematologica 2005;90:1680-1692.
10. Horning SJ. Natural history of and therapy for the indolent non-Hodgkins lymphomas. Semin Oncol 1993;20(5 Suppl. 5):75-88.
11. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkins lymphomas. N Engl J Med 1984;311:1471-1475.
12. Mounter PJ, Lennard AL. Management of non-Hodgkins lymphomas. Postgrad Med J 1999;75:2-6.
13. Redman J, Cabanillas F, McLaughlin P, et al. Fludarabine monophosphate (FAMP) treatment of low-grade lymphoma (LGL). Proc Am Soc Clin Oncol 1991;283:989.
14. Solal-Céligny P, Brice P, Brousse N, et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma. A multicentre study by the Groupe dEtude des Lymphomes de lAdulte. J Clin Oncol 1996;14:514-519.
15. Kay AC, Saven A, Carrera CJ, et al. 2-chlorodeoxyadenosine treatment of lowgrade lymphomas. J Clin Oncol 1992;10:371-377.
16. Saven A, Emanuele S, Kosty M, Koziol J, Ellison D, Piro L. 2-chlorodeoxyadenosine activity in patients with untreated indolent non-Hodgkins lymphoma. Blood 1995;86:1710-1716.
17. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-1423.
18. Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005;23: 8447-8452.
19. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a fourdose treatment program. J Clin Oncol 1998;16:2825-2833.
20. DeNardo SJ, Kroger LA, DeNardo GL. A new era for radiolabeled antibodies in cancer? Curr Opin Immunol 1999;11:563-569.
21. Zelenetz A. Radioimmunotherapy for lymphoma. Curr Opin Oncol 1999;11:375-380.
22. Witzig TE, White CA, Gordon LI, et al. Prospective randomized controlled study of ZevalinTM (IDEC-Y2B8) radioimmunotherapy compared to rituximab immunotherapy for B-cell NHL: report of interim results. Blood 1999;94:(Abstract 631).
23. Matasar M, Zelenetz A. Overview of lymphoma diagnosis and management. Radiol Clin N Am 2008;46:175-198.
24. Toze CL, Barnett MJ, Connors JM, et al. Long-term diseasefree survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation. Br J Haematol 2004;127:311-321.
25. van Besien K, Loberiza FR Jr, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003;102: 3521-3529. (Pubitemid 37409366)
26. Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 2009;27:1202-1208.
27. Matasar MJ, Saxena R, Wong EK, Filippa DA, Zelenetz AD. Practice patterns in the diagnosis of follicular lymphoma (FL): report from the national lymphomacare study (NLCS). Blood 2007;110:(Abstract 2613).
28. Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104: 1258-1265.
29. Nabhan C, Taylor MF, Hirata J, et al. Racial disparities in disease presentation, treatment, and response rates for follicular lymphoma (FL) in the United States (US): report from the National LymphoCare Study (NLCS). Blood 2009;114:(Abstract 1381).
30. Ardeshna KM, Smith P, Norton A, et al. British national lymphoma investigation. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003;362:516-522.
31. Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007;99:706-714.
32. Solal-Céligny P, Imrie K, Belch A, et al. Mabthera (rituximab) plus CVP chemotherapy for first-line treatment of stage III/IV follicular non-Hodgkins lymphoma (NHL): confirmed efficacy with longer follow-up. Blood (ASH Annual Meeting Abstracts) 2005;106 (Suppl.): (Abstract 350).
33. Hiddeman W, Forstpointer R, Kneba M, et al. The addition of rituximab to combination chemotherapy with CHOP has a long lasting impact on subsequent treatment in remission in follicular lymhoma but not in mantle cell lymphoma: results of two prospective randomized studies of the German low grade lymphoma study group (GLSG). Blood (ASH Annual Meeting Abstracts) 2004;104 (Suppl.): (Abstract 161).
34. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295-3301.
35. Al-Tourah AJ, Gill KK, Hoskins PJ, et al. The impact of initial treatment of advanced stage indolent lymphoma on the risk of transformation. J Clin Oncol (ASCO Annual Meeting Proceedings Part I) 2006;24 (Suppl.): (Abstract 7510).
36. Montoto S, Davies AJ, Matthews J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 2007;25:2426-2433.
37. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumorinfiltrating immune cells. N Engl J Med 2004;351:2159-2169.
38. Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005;106:2169-2174.
39. Carreras J, Lopez-Guillermo A, Fox BC, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006;108:2957-2964.
40. Lee AM, Clear AJ, Calaminici M, et al. Number of CD4cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 2006;24:5052-5059.
41. Alvaro T, Lejeune M, Salvadó MT, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 2006;24:5350-5357.
42. Glas AM, Knoops L, Delahaye L, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 2007;25:390-398.
43. de Jong D, Koster A, Hagenbeek A, et al. Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica 2009;94:70-77.
44. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Vant Veer MB, Bartelink H, van Leeuwen FE. Long-term causespecific mortality of patients treated for Hodgkins disease. J Clin Oncol 2003;21:3431-3439.
45. Aleman BM, van den Belt-Dusebout AW, De BruinML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007;109:1878-1886.
46. Hjermstad MJ, Oldervoll L, Fosså SD, Holte H, Jacobsen AB, Loge JH. Quality of life in long-term Hodgkins disease survivors with chronic fatigue. Eur J Cancer 2006;42:327-333.
47. Rueffer U, Breuer K, Josting A, et al. Male gonadal dysfunction in patients with Hodgkins disease prior to treatment. Ann Oncol 2001;12:1307-1311.
48. Sieniawski M, Reineke T, Nogova L, et al. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood 2008;111:71-76.
49. Mattle V, Behringer K, Engert A, Wildt L. Female fertility after cytotoxic therapy- protection of ovarian function during chemotherapy of malignant and non-malignant diseases. Eur J Haematol Suppl 2005;66:77-82.
50. Matasar MJ, McCallen LN, Riedel ER, Ford JS, Oeffinger KC, Straus DJ. Late mortality and morbidity of patients with Hodgkin lymphoma treated in adulthood. J Clin Oncol 2009;27 (Suppl.): (Abstract 8547).
51. Ford JS, Schwartz J, McCallen LN, et al. Psychosocial functioning in survivors of Hodgkin lymphoma (HL) treated during adulthood. J Clin Oncol 2008;26 (Suppl.): (Abstract 9592).
52. Huang XJ, Wang Y, Liu DH, et al. Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia- feasibility and safety study. J Clin Immunol 2008;28:390-397.
53. Bollard CM, Gottschalk S, Leen AM, et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 2007;110:2838-2845.
54. Heslop HE, Slobod KS, Pule MA, et al. Long term outcome of EBV specific T-cell infusions to prevent or treat EBVrelated lymphoproliferative disease in transplant recipients. Blood 2010;115:925-935.
55. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol 2002;20:70-75.
56. Vera J, Savoldo B, Vigouroux S, et al. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 2006;108:3890-3897.
57. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008;14:1264-1270.
58. Bollard CM, Rössig C, Calonge MJ, et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 2002;99: 3179-3187.
59. Foster AE, Dotti G, Lu A, et al. Antitumor activity of EBVspecific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother 2008;31:500-505.
60. Di Stasi A, De Angelis B, Rooney CM, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 2009;113:6392-6402.